Journal
NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-03524-1
Keywords
-
Categories
Funding
- Medical Research Council
- Guy's and St Thomas Charity
- Worldwide Cancer Research
- Prostate Cancer UK
- Academy of Medical Sciences
- Experimental Cancer Medicine Centre at King's College London
- King's Health Partners/King's College London Cancer Research UK Cancer Centre
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London
- Breast Cancer Now
- MRC [MR/L006278/1] Funding Source: UKRI
- Medical Research Council [MR/L006278/1] Funding Source: researchfish
- Medical Research Foundation [MRF-152-0002-STD-PAPA] Funding Source: researchfish
Ask authors/readers for more resources
The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of CD19+ B-cell malignancy has established a new therapeutic pillar of hematology-oncology. Nonetheless, formidable challenges remain for the attainment of comparable success in patients with solid tumors. To accelerate progress and rapidly characterize emerging toxicities, systems that permit the repeated and non-invasive assessment of CAR T-cell bio-distribution would be invaluable. An ideal solution would entail the use of a non-immunogenic reporter that mediates specific uptake of an inexpensive, non-toxic and clinically established imaging tracer by CAR T cells. Here we show the utility of the human sodium iodide symporter (hNIS) for the temporal and spatial monitoring of CAR T-cell behavior in a cancer-bearing host. This system provides a clinically compliant toolkit for high-resolution serial imaging of CAR T cells in vivo, addressing a fundamental unmet need for future clinical development in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available